Market Overview

UPDATE: Stifel Nicolaus Increases PT to $168 on Biogen Idec on Hemophilia Trial

Share:
Related BIIB
Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS
Government Study: Cellphone Radiation Linked To Cancer
European Ad Comm backs expanded use of Biogen's Tysabri in RRMS patients (Seeking Alpha)

Stifel Nicolaus reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) and increased its price target from $167 to $168.

Stifel Nicolaus commented, "Biogen and partner Swedish Orphan Biovitrum (Sobi) announced positive top-line data from the Phase III B-LONG trial of rFIXFc, a long-acting blood clotting factor, in patients with hemophilia B. This condition is currently typically treated with market leader BeneFIX (Pfizer; 2011 WW sales $693M). … We see the B-LONG data as sufficient for rFIXFc approval; we expect a 1H13 filing and mid 2014 launch."

Biogen Idec closed at $151.62 on Wednesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Apr 2016Goldman SachsMaintainsNeutral
Apr 2016BMO CapitalInitiates Coverage onMarket Perform
Mar 2016BairdMaintainsNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!